Browse the corpus

Immune hemolytic anemias are disorders characterized by the immune system targeting and destroying red blood cells (RBCs). The etiology of these anemias is multifaceted, involving autoimmune, alloimmune, and drug-induced mechanisms. Furthermore, this leads to conditions such as warm autoimmune hemolytic anemia (AIHA), cold agglutinin disease, mixed AIHA, paroxysmal cold hemoglobinuria, and drug-induced hemolytic anemia. Diagnosing different types of immune hemolytic anemia requires a detailed interpretation of several laboratory tests, including complete blood count (CBC), haptoglobin, lactate dehydrogenase, reticulocyte count, unconjugated bilirubin, direct and indirect antiglobulin tests, and peripheral blood smears. Accurate diagnosis and management of these conditions through comprehensive laboratory evaluation improve patient outcomes and elevate the standard of care in hematology and transfusion medicine. This activity provides a comprehensive overview of the etiology, epidemiology, pathophysiology, and diagnostic evaluation of immune hemolytic anemias, highlighting the complex interplay of immune mechanisms that result in RBC destruction and anemia. This activity helps interprofessional healthcare providers diagnose symptoms accurately, administer tailored treatments, and deliver comprehensive patient care. In addition, this activity allows clinicians to anticipate and manage potential complications, elevating the overall standard of care in hematology and transfusion medicine. Objectives: Identify the key laboratory tests required for the diagnosis of immune hemolytic anemias. Apply knowledge of antibody specificity and antigen reactivity in selecting appropriate blood products for transfusion. Select optimal treatment strategies based on laboratory results and patient-specific factors. Collaborate with multidisciplinary healthcare providers, including hematologists and immunologists, to interpret complex laboratory findings in immune hemolytic anemias. Access free multiple choice questions on this topic.

Immune hemolytic anemias are disorders characterized by the immune system targeting and destroying red blood cells (RBCs). These conditions are classified based on factors such as the type of antibody involved, the temperature when hemolysis occurs, and whether the hemolysis is extravascular or intravascular. The immune-mediated destruction of RBCs can occur through several mechanisms, including the production of autoantibodies against self-antigens on RBCs, alloantibodies directed against foreign antigens on transfused RBCs, or drug-induced antibodies that bind to RBCs or trigger complement activation. Immune hemolytic anemias are categorized into autoimmune, alloimmune, and drug-induced mechanisms, each with unique etiologies and pathophysiological processes. Autoimmune hemolytic anemias (AIHAs) include warm AIHA, cold agglutinin disease, and mixed-type AIHA. The most common form of AIHA is warm AIHA, which is mediated by immunoglobulin G (IgG) antibodies and is often associated with hematologic, autoimmune, and infectious conditions. Cold agglutinin disease involves IgM antibodies that react at cold temperatures, and paroxysmal cold hemoglobinuria features an IgG autoantibody causing hemolysis upon rewarming. Alloimmune hemolytic anemia occurs when alloantibodies attack foreign RBC antigens, typically following blood transfusions or during hemolytic disease of the newborn. Drug-induced immune hemolytic anemia (DIIHA) occurs when drug-induced antibodies bind to and destroy RBCs. Laboratory evaluation is crucial for diagnosing and managing immune hemolytic anemias. Diagnostic tests include complete blood count (CBC), haptoglobin, lactate dehydrogenase (LDH), reticulocyte count, bilirubin levels, and direct antiglobulin test (DAT) or indirect antiglobulin test. Peripheral blood smears, tests for cold agglutinins, Donath-Landsteiner antibodies, and other specialized tests are essential for accurate diagnosis.

The detailed pathophysiology of autoimmune hemolytic anemias is mentioned below, focusing on the primary target antigens and corresponding DAT biomarkers (see Table 2. Pathophysiology of Autoimmune Hemolytic Anemia). Warm Autoimmune Hemolytic Anemia Warm AIHA occurs when the body's immune system mistakenly attacks its own RBCs, destroying them. This type of anemia can occur spontaneously without any apparent cause, known as primary or idiopathic warm AIHA, or it can develop secondary to certain underlying conditions or medications that trigger the production of autoantibodies targeting RBCs. The autoantibodies involved in warm AIHA are predominantly of the IgG type, although IgA and warm-acting IgM antibodies have also been reported. Subtypes of IgG, such as IgG1 and IgG3, can activate the complement system and cause more severe hemolysis than other subtypes. These antibodies typically target common antigens found on the surface of RBCs, with the most frequently targeted antigens including those of the Rh complex and glycophorin antigens, which are heavily glycosylated proteins on the membrane.[2][14] In warm AIHA, the primary site of hemolysis is extravascular, predominantly within lymphoid organs such as the spleen. This process is primarily mediated by the Fc fragment of IgG through antibody-dependent cellular cytotoxicity. Minimal hemolysis is attributed to complement coating in warm AIHA. This leads to the formation of small, round cells called microspherocytes, which are less malleable than normal RBCs and can become trapped in the spleen's sinusoids, prolonging their destruction. In severe cases, intravascular hemolysis may occur if the reticuloendothelial system is overwhelmed or if the complement membrane attack complex is deposited on the surface of RBCs.[3] Approximately 50% to 60% of warm AIHA cases are associated with underlying conditions, while the remaining cases are considered primary or idiopathic. Underlying conditions linked to secondary warm AIHA include various infections such as HIV, Epstein-Barr virus, hepatitis C, and, more recently, hepatitis E virus.[8] Recently, COVID-19-associated warm AIHA has been reported.[7] In addition, autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, or ulcerative colitis have been associated with warm AIHA.

Approximately 50% to 60% of warm AIHA cases are associated with underlying conditions, while the remaining cases are considered primary or idiopathic. Underlying conditions linked to secondary warm AIHA include various infections such as HIV, Epstein-Barr virus, hepatitis C, and, more recently, hepatitis E virus.[8] Recently, COVID-19-associated warm AIHA has been reported.[7] In addition, autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, or ulcerative colitis have been associated with warm AIHA. Lymphoproliferative disorders such as autoimmune lymphoproliferative syndrome, chronic lymphocytic leukemia (CLL), lymphoma, and monoclonal gammopathies are also associated with warm AIHA. Immunodeficiency states, especially inherited immunodeficiency, hematopoietic stem cell transplantation, solid organ transplantation, and hypogammaglobulinemia, can also precipitate warm AIHA.[15] Rarely, pregnancy and medications can trigger warm AIHA. Some unique causes include Babesiosis in asplenic patients and bites from the Brown recluse spider.[16][17] Cold Agglutinin Disease Cold agglutinin disease is a rare autoimmune disorder characterized by autoantibodies, primarily of the IgM class, which exhibit reactivity against RBCs at temperatures below normal body temperature. Occasionally, IgG and IgA cold agglutinins have been reported, although IgA cold agglutinin does not cause cold agglutinin disease. The pathophysiology involves a complex interplay of immune mechanisms that culminate in the destruction of RBCs and subsequent anemia.[11][18][19] The underlying trigger for cold agglutinin disease is the production of autoantibodies by the immune system.[20] These autoantibodies typically target antigens, such as the I/i, GLOB, or P antigens, on the surface of RBCs.

Cold agglutinin disease is a rare autoimmune disorder characterized by autoantibodies, primarily of the IgM class, which exhibit reactivity against RBCs at temperatures below normal body temperature. Occasionally, IgG and IgA cold agglutinins have been reported, although IgA cold agglutinin does not cause cold agglutinin disease. The pathophysiology involves a complex interplay of immune mechanisms that culminate in the destruction of RBCs and subsequent anemia.[11][18][19] The underlying trigger for cold agglutinin disease is the production of autoantibodies by the immune system.[20] These autoantibodies typically target antigens, such as the I/i, GLOB, or P antigens, on the surface of RBCs. When the body is exposed to colder temperatures, particularly below 37 °C, these IgM autoantibodies bind to multiple RBCs, causing agglutination or clumping—a process known as cold agglutination.[21] This phenomenon is the hallmark of cold agglutinin disease and is responsible for many clinical manifestations. In cold agglutinin disease, IgM autoantibodies to RBCs bind to C1q, triggering activation of the complement cascade, a critical part of the innate immune response.[22][23] Complement proteins, particularly C3b, are deposited on the surface of RBCs, which promotes their destruction. This complement activation enhances the opsonization of RBCs, making them more susceptible to phagocytosis by macrophages in the reticuloendothelial system, particularly in the liver by Kupffer cells, resulting in extravascular hemolysis.[24] Less commonly, in about 15% of cases, complement activation facilitates the formation of the membrane attack complex, leading to direct lysis of RBCs and subsequent hemoglobinuria, indicating intravascular hemolysis.[25]

When the body is exposed to colder temperatures, particularly below 37 °C, these IgM autoantibodies bind to multiple RBCs, causing agglutination or clumping—a process known as cold agglutination.[21] This phenomenon is the hallmark of cold agglutinin disease and is responsible for many clinical manifestations. In cold agglutinin disease, IgM autoantibodies to RBCs bind to C1q, triggering activation of the complement cascade, a critical part of the innate immune response.[22][23] Complement proteins, particularly C3b, are deposited on the surface of RBCs, which promotes their destruction. This complement activation enhances the opsonization of RBCs, making them more susceptible to phagocytosis by macrophages in the reticuloendothelial system, particularly in the liver by Kupffer cells, resulting in extravascular hemolysis.[24] Less commonly, in about 15% of cases, complement activation facilitates the formation of the membrane attack complex, leading to direct lysis of RBCs and subsequent hemoglobinuria, indicating intravascular hemolysis.[25] Cold agglutinin disease is classified into primary (idiopathic) or secondary forms. Primary cold agglutinin disease involves cold agglutinin-mediated destruction of RBCs and extravascular hemolysis without an underlying disorder. Patients with primary cold agglutinin disease often have a low-grade clonal lymphoproliferative bone marrow disorder.[26] Secondary cold agglutinin syndrome is typically precipitated by an underlying infection, autoimmune disease, or overt lymphoma. In older patients, cold agglutinin disease often presents as a primary disease with an underlying lymphoid malignancy such as B-cell or plasma cell disorders, aggressive non-Hodgkin lymphoma, or Waldenström macroglobulinemia. Although solid tumors are rarely associated with primary cold agglutinin disease, this association is mostly uncommon.[27] Younger patients are more likely to have secondary cold agglutinin disease precipitated from infection, commonly M pneumoniae or Epstein-Barr infection.[28][29] Cases have been reported of infections precipitating secondary cold agglutinin disease from HIV, influenza, rubella, varicella-zoster virus, and COVID-19.[30][31][32][33][34] Paroxysmal Cold Hemoglobinuria

Cold agglutinin disease is classified into primary (idiopathic) or secondary forms. Primary cold agglutinin disease involves cold agglutinin-mediated destruction of RBCs and extravascular hemolysis without an underlying disorder. Patients with primary cold agglutinin disease often have a low-grade clonal lymphoproliferative bone marrow disorder.[26] Secondary cold agglutinin syndrome is typically precipitated by an underlying infection, autoimmune disease, or overt lymphoma. In older patients, cold agglutinin disease often presents as a primary disease with an underlying lymphoid malignancy such as B-cell or plasma cell disorders, aggressive non-Hodgkin lymphoma, or Waldenström macroglobulinemia. Although solid tumors are rarely associated with primary cold agglutinin disease, this association is mostly uncommon.[27] Younger patients are more likely to have secondary cold agglutinin disease precipitated from infection, commonly M pneumoniae or Epstein-Barr infection.[28][29] Cases have been reported of infections precipitating secondary cold agglutinin disease from HIV, influenza, rubella, varicella-zoster virus, and COVID-19.[30][31][32][33][34] Paroxysmal Cold Hemoglobinuria Paroxysmal cold hemoglobinuria is an acquired hemolytic anemia characterized by an IgG autoantibody that activates complement in cold temperatures, resulting in intravascular hemolysis upon rewarming, accompanied by hemoglobinuria. The exact mechanisms triggering autoantibody formation remain unclear, but this typically arises in the context of infections or autoimmune disorders, suggesting immune stimulation of autoantibody production. A proposed mechanism involves the generation of cross-reacting antibodies that target viral or bacterial antigens mimicking the P antigen on RBCs.

Paroxysmal cold hemoglobinuria is an acquired hemolytic anemia characterized by an IgG autoantibody that activates complement in cold temperatures, resulting in intravascular hemolysis upon rewarming, accompanied by hemoglobinuria. The exact mechanisms triggering autoantibody formation remain unclear, but this typically arises in the context of infections or autoimmune disorders, suggesting immune stimulation of autoantibody production. A proposed mechanism involves the generation of cross-reacting antibodies that target viral or bacterial antigens mimicking the P antigen on RBCs. The autoantibody in paroxysmal cold hemoglobinuria exhibits distinct characteristics, including specificity for the RBC GLOB antigen (formerly known as the P antigen)—a polysaccharide antigen on the RBC surface.[35] These antibodies are polyclonal, derived from multiple B-cell clones, and predominantly of the IgG class.[36] Unlike cold agglutinins, which are typically IgM antibodies that induce RBC agglutination, these antibodies do not cause agglutination but instead bind to RBCs below normal body temperature. Upon rewarming, the antibodies dissociate, but complement proteins remain attached to RBCs, leading to complement-mediated intravascular hemolysis—a hallmark of the anemia. Diagnosis of the anemia relies on detecting the presence of the Donath-Landsteiner antibody, which fixes complement in cold temperatures, contributing to intravascular hemolysis upon rewarming.[37] Historically, paroxysmal cold hemoglobinuria was described as a chronic condition in patients afflicted with tertiary or congenital syphilis. However, currently, the anemia is often precipitated by infections, especially upper respiratory tract infections, gastroenteritis, and M pneumoniae. Autoimmune disease and lymphoproliferative disorders have been associated, although to a lesser extent (<10%) when compared to infectious etiology.[10] Mixed Autoimmune Hemolytic Anemia

Diagnosis of the anemia relies on detecting the presence of the Donath-Landsteiner antibody, which fixes complement in cold temperatures, contributing to intravascular hemolysis upon rewarming.[37] Historically, paroxysmal cold hemoglobinuria was described as a chronic condition in patients afflicted with tertiary or congenital syphilis. However, currently, the anemia is often precipitated by infections, especially upper respiratory tract infections, gastroenteritis, and M pneumoniae. Autoimmune disease and lymphoproliferative disorders have been associated, although to a lesser extent (<10%) when compared to infectious etiology.[10] Mixed Autoimmune Hemolytic Anemia Mixed AIHA is a multifaceted hematological disorder characterized by the simultaneous presence of autoantibodies targeting different antigens on RBCs, resulting in hemolysis and anemia.[23] The immune pathology underlying mixed AIHA involves diverse mechanisms contributing to RBC destruction and associated clinical manifestations. Autoantibodies in mixed AIHA can target various RBC antigens, including Rh, Kell, Duffy, and others, reflecting the heterogeneous nature of the immune response in this condition. The etiology of autoantibody production in mixed AIHA is often associated with underlying conditions such as autoimmune diseases, infections, or malignancies, which trigger immune dysregulation and stimulate the production of autoantibodies against RBC antigens.[21] This process may involve molecular mimicry, where antigens from infectious agents or tumor cells share structural similarities with RBC antigens, leading to the production of cross-reactive antibodies. Complement activation is a critical aspect of the immune pathology in mixed AIHA, as complement-fixing autoantibodies initiate the complement cascade, resulting in complement-mediated hemolysis.[22] This phenomenon involves depositing complement proteins on RBCs, which leads to their destruction through opsonization and the formation of the membrane attack complex. Drug-Induced Immune Hemolytic Anemia

The etiology of autoantibody production in mixed AIHA is often associated with underlying conditions such as autoimmune diseases, infections, or malignancies, which trigger immune dysregulation and stimulate the production of autoantibodies against RBC antigens.[21] This process may involve molecular mimicry, where antigens from infectious agents or tumor cells share structural similarities with RBC antigens, leading to the production of cross-reactive antibodies. Complement activation is a critical aspect of the immune pathology in mixed AIHA, as complement-fixing autoantibodies initiate the complement cascade, resulting in complement-mediated hemolysis.[22] This phenomenon involves depositing complement proteins on RBCs, which leads to their destruction through opsonization and the formation of the membrane attack complex. Drug-Induced Immune Hemolytic Anemia Immune-mediated destruction of RBCs primarily involves antibody-mediated mechanisms, where various antigen-antibody interactions lead to opsonization and subsequent phagocytosis by reticuloendothelial macrophages in the spleen and/or liver, resulting in extravascular hemolysis. While the DAT (or the direct Coombs test) is typically positive, occasionally, a drug metabolite rather than the parent drug itself may be responsible, complicating diagnosis. This anemia can be categorized by different mechanisms, including drug-dependent reactions and alteration of RBC surface antigens. In drug-dependent reactions, the drug binds to RBCs and becomes part of the antigen-antibody complex, remaining firmly bound to the membrane or causing immune complex formation. RBC surface antigens are altered when drugs modify normal membrane components, leading to immune hemolysis weeks to months after drug initiation.[38][39]

Immune-mediated destruction of RBCs primarily involves antibody-mediated mechanisms, where various antigen-antibody interactions lead to opsonization and subsequent phagocytosis by reticuloendothelial macrophages in the spleen and/or liver, resulting in extravascular hemolysis. While the DAT (or the direct Coombs test) is typically positive, occasionally, a drug metabolite rather than the parent drug itself may be responsible, complicating diagnosis. This anemia can be categorized by different mechanisms, including drug-dependent reactions and alteration of RBC surface antigens. In drug-dependent reactions, the drug binds to RBCs and becomes part of the antigen-antibody complex, remaining firmly bound to the membrane or causing immune complex formation. RBC surface antigens are altered when drugs modify normal membrane components, leading to immune hemolysis weeks to months after drug initiation.[38][39] Oxidative stress from certain drugs can induce hemolysis, especially in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or hemoglobin (Hb) H disease.[40] Oxidant injury forms oxidizing radicals, leading to hemolysis via oxygen radical damage to RBC membrane components and cellular proteins. Additionally, drug-induced hemolysis can result in methemoglobinemia and thrombotic microangiopathy, necessitating prompt recognition and management.[41] More than 130 drugs have been associated with DIIHA.[42] Immune hemolytic anemia is frequently triggered by antibiotics, particularly cephalosporins and penicillins. Certain anti-cancer drugs, such as fludarabine, platinum compounds, and immune checkpoint inhibitors, are common culprits.[5][6][43] Table Table 2. Pathophysiology of Autoimmune Hemolytic Anemia. Alloimmune Hemolytic Anemia

Oxidative stress from certain drugs can induce hemolysis, especially in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or hemoglobin (Hb) H disease.[40] Oxidant injury forms oxidizing radicals, leading to hemolysis via oxygen radical damage to RBC membrane components and cellular proteins. Additionally, drug-induced hemolysis can result in methemoglobinemia and thrombotic microangiopathy, necessitating prompt recognition and management.[41] More than 130 drugs have been associated with DIIHA.[42] Immune hemolytic anemia is frequently triggered by antibiotics, particularly cephalosporins and penicillins. Certain anti-cancer drugs, such as fludarabine, platinum compounds, and immune checkpoint inhibitors, are common culprits.[5][6][43] Table Table 2. Pathophysiology of Autoimmune Hemolytic Anemia. Alloimmune Hemolytic Anemia Alloimmune hemolytic anemia occurs when the immune system produces antibodies against RBC antigens perceived as foreign. This immune response can lead to the destruction of RBCs, resulting in anemia. Alloimmune hemolytic anemia can be triggered by several scenarios, most importantly incompatible blood transfusions and hemolytic disease of the fetus and newborn. Acute hemolytic transfusion reactions are typically caused by ABO incompatibility, most often due to clerical or procedural errors. These reactions involve the rapid destruction of RBCs when the recipient's immune system attacks transfused cells because they express an antigen foreign to the recipient. In rare instances, hemolysis can occur when transfused plasma contains antibodies targeting the recipient's RBC antigens. However, this is generally less severe due to the immediate dilution of donor antibodies upon transfusion.

Alloimmune hemolytic anemia occurs when the immune system produces antibodies against RBC antigens perceived as foreign. This immune response can lead to the destruction of RBCs, resulting in anemia. Alloimmune hemolytic anemia can be triggered by several scenarios, most importantly incompatible blood transfusions and hemolytic disease of the fetus and newborn. Acute hemolytic transfusion reactions are typically caused by ABO incompatibility, most often due to clerical or procedural errors. These reactions involve the rapid destruction of RBCs when the recipient's immune system attacks transfused cells because they express an antigen foreign to the recipient. In rare instances, hemolysis can occur when transfused plasma contains antibodies targeting the recipient's RBC antigens. However, this is generally less severe due to the immediate dilution of donor antibodies upon transfusion. The first step involves recipient antibodies attaching to antigens on transfused RBCs. This typically requires prior sensitization through previous exposure, such as a prior transfusion or pregnancy. Patients with blood groups O, A, and B continuously produce antibodies against the A and B antigens they lack, often due to exposure to similar antigens on intestinal microorganisms. These naturally occurring antibodies, particularly IgM, can quickly activate complement, leading to rapid intravascular hemolysis in cases of ABO incompatibility. In some cases, transfusion with blood products containing high titers of ABO alloantibodies can also trigger a reaction. In hemolytic disease of the fetus and newborn, maternal sensitization in an RhD-negative individual occurs due to previous exposure to the Rh antigen, either through transfusion with Rh-positive RBCs or pregnancy with an Rh-positive offspring. Consequently, Rh hemolytic disease of the newborn generally does not occur in the first pregnancy in the absence of a transfusion history. Immunologically, antibody secretion begins with IgM, which cannot cross the placental barrier. This is later followed by isotype switching, leading to the production of IgG antibodies. IgG antibodies can cross the placental barrier, and they do so during the second and subsequent pregnancies, attacking the fetal RBCs and causing hemolysis and associated complications such as hydrops fetalis and jaundice.

In hemolytic disease of the fetus and newborn, maternal sensitization in an RhD-negative individual occurs due to previous exposure to the Rh antigen, either through transfusion with Rh-positive RBCs or pregnancy with an Rh-positive offspring. Consequently, Rh hemolytic disease of the newborn generally does not occur in the first pregnancy in the absence of a transfusion history. Immunologically, antibody secretion begins with IgM, which cannot cross the placental barrier. This is later followed by isotype switching, leading to the production of IgG antibodies. IgG antibodies can cross the placental barrier, and they do so during the second and subsequent pregnancies, attacking the fetal RBCs and causing hemolysis and associated complications such as hydrops fetalis and jaundice. Hemolytic transfusion reactions can involve both intravascular and extravascular RBC destruction. When an antigen-antibody complex forms, it may activate the classical complement pathway. Complete complement activation on the RBC surface results in the formation of the membrane attack complex and causes intravascular hemolysis. If complement activation halts at the level of C3b, RBCs coated with IgG and C3b are primarily destroyed by macrophages in the liver. Destruction of RBCs coated with C3b is less effective. RBCs coated only with IgG are removed from circulation in the spleen. These cells can also be destroyed by macrophages or through antibody-dependent cellular cytotoxicity involving large lymphocytes (K cells) releasing perforins. Both intravascular and extravascular hemolysis can occur in acute and delayed hemolytic transfusion reactions, although their relative contributions may vary.[13][44][45]

Utilizing a multidisciplinary approach significantly enhances healthcare outcomes in managing immune hemolytic anemia by capitalizing on collaborative efforts tailored to this complex condition. Timely diagnosis and treatment are imperative due to the potential for rapid disease progression and life-threatening complications. Unlike other forms of anemia, immune hemolytic anemia involves the immune-mediated destruction of RBCs, leading to acute anemia and associated symptoms such as fatigue, weakness, shortness of breath, and pallor. Prompt diagnosis is essential to prevent severe complications, including hemolytic crises, acute kidney injury, cardiovascular instability, and death. The underlying autoimmune processes may also be associated with systemic manifestations or comorbidities that require timely identification and intervention. Given the urgency of prompt intervention, a multidisciplinary approach involving physicians, hematologists, immunologists, laboratory technicians, nursing staff, and pharmacists is crucial. In this collaborative framework, the interprofessional healthcare team collaborates with hematologists and immunologists to interpret laboratory findings related to immune hemolytic anemia, diagnose underlying autoimmune processes, and devise individualized treatment plans tailored to the specific subtype of immune hemolytic anemia. Hematologists and immunologists contribute their expertise in understanding the pathophysiology and guiding treatment decisions. Laboratory technicians play a crucial role by performing the direct Coombs test, which detects immune-mediated hemolysis by identifying antibodies bound to RBCs. Their meticulous work ensures accurate and timely results, providing essential information for diagnosis and treatment monitoring.

In this collaborative framework, the interprofessional healthcare team collaborates with hematologists and immunologists to interpret laboratory findings related to immune hemolytic anemia, diagnose underlying autoimmune processes, and devise individualized treatment plans tailored to the specific subtype of immune hemolytic anemia. Hematologists and immunologists contribute their expertise in understanding the pathophysiology and guiding treatment decisions. Laboratory technicians play a crucial role by performing the direct Coombs test, which detects immune-mediated hemolysis by identifying antibodies bound to RBCs. Their meticulous work ensures accurate and timely results, providing essential information for diagnosis and treatment monitoring. Nursing staff are pivotal in patient advocacy, monitoring for signs of hemolysis, administering treatments, and educating patients and families about the disease process and lifestyle modifications. By harnessing the collective skills and expertise of the multidisciplinary healthcare team, prompt diagnosis and treatment are facilitated, thereby reducing the risk of complications associated with untreated immune hemolytic anemia. Effective coordination and communication among healthcare team members ensures comprehensive care delivery, ultimately improving healthcare outcomes and enhancing the quality of life for patients with immune hemolytic anemia.